



## **Dra. Leticia Calahorra Melero, PhD**

Postdoctoral researcher

Neuroinmuno- Repair Group (Lab i2-04, office i2-12)

National Hospital for Paraplegics-SESCAM.

Toledo, Spain

ORCID code: [orcid.org/0000-0001-6146-8916](https://orcid.org/0000-0001-6146-8916)

### **1.- ACADEMIC DEGREES**

- Bachelor of Biochemistry (2011). Universidad de Zaragoza. Zaragoza, Spain.
- M.S in Immunology Research (2012). Universidad de Alcalá. Madrid, Spain.
- PhD. In Biomedical Research (2018). Universidad Complutense de Madrid. Madrid, Spain.

### **2.- RESEARCH AND PROFESSIONAL EXPERIENCE**

- **2011:** Undergraduate student. Microbiology department. Hospital Universitario Miguel Servet. Zaragoza, Spain.
- **2012- 2019:** PhD student. Clinic Immunology group. Instituto de Investigación Sanitaria Gregorio Marañón. Madrid, Spain.
- **2021- to date:** Research fellow, supported by Instituto de Salud Carlos III. Development Neurobiology group. Hospital Nacional de Paraplégicos. Toledo, Spain.

### **3.- PUBLICATIONS**

#### ***Original Papers***

- **2020:** Sarmiento E, Lopez-Hoyos M, **Calahorra L**, Carbone J et al. *Secondary antibody deficiency is associated with development of infection in kidney transplantation: Results of a multicenter study.* J.Transpl Infect Dis. 2020. Online ahead of print.
  
- **2018:** Sarmiento E, Cifrian J, **Calahorra L**, Carbone J et al. *Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study.* J Heart Lung Transplant. 2018; 37(8): 1001-1012.
  
- **2017:** Sarmiento E, Jaramillo M, **Calahorra L**, Carbone J et al. *Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study.* J Heart Lung Transplant. 2017; 36(5): 529-539.
  
- **2016:** Sarmiento E, Diez P, Arraya M, Jaramillo M, **Calahorra L**, Carbone J et al. *Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial.* Transpl Infect Dis. 2016; 18(6): 832-843.
  
- **2015:** Carbone J, **Calahorra L**, Navarro J, Sarmiento E. *Potential role of serum BAFF as a biomarker in HIV infection.* Infect Dis (Lond). 2015; 47(4): 260-262.
  
- **2013:** Lanio N, Sarmiento E, Gallego A, **Calahorra L**, Carbone J et al. *Alterations of naïve and memory B-cell subsets are associated with risk of rejection and infection in heart recipients.* Transpl Int. 2013; 26(8): 800-812.

### **4.- SCIENTIFIC COMMUNICATIONS IN NATIONAL/INTERNATIONAL CONFERENCES**

#### **- 2019**

**Calahorra L**, Sarmiento E, Cifrián J, Laporta R et al. *Pre Transplant Interleukin 10 levels are higher in lung recipients with post transplant infections.* ISHLT 39th Annual Meeting and Scientific Sessions. The Journal Heart and Lung Transplantation. 2019. Vol. 38. Issue 4, S220–S221.

#### **- 2017**

**Calahorra L**, Sarmiento E, Gallego A, García S et al. *Lower pre- transplant memory class-switched B cell levels are associated with a high risk of severe infection after heart*

*transplantation*. ISHLT 37th Annual Meeting and Scientific Sessions. The Journal of Heart and Lung Transplantation. 2017. Vol.36, Issue 50–51.

**Calahorra L**, Cifrian J, Sarmiento E, Izzahouri I, et al. *Elevated serum BAFF levels are associated with an increased risk of acute rejection in lung recipients*. ISHLT 37th Annual Meeting and Scientific Sessions. The Journal of Heart and Lung Transplantation. 2017. Vol. 36. Issue 4, S402.

- **2016**

Carbone J, Gallego A, **Calahorra L**, Sousa I, et al. *CD38+DR+ expression on peripheral monocytes and TLR2 expression on plasmacytoid dendritic cells may be early markers for severe infection in heart transplantation*. ISHLT 36th Annual Meeting and Scientific Sessions. The Journal of Heart and Lung Transplantation. 2017, Vol. 35. Issue 4S283.

-**2015**

**Calahorra L**, Sarmiento E, Souza I, Díez P. *Elevated pretransplantation soluble BAFF: a new biomarker for acute cellular rejection risk?* 17th Congress of the European Society for Organ Transplantation. 2015.

- **2013**

**Calahorra L**, Sarmiento E, Fernández- Cruz E, Carbone J. *Increased levels of serum BAFF are associated with higher CD4+ and CD8+ T-cell activated subsets in HIV infection*. XXXVII Congreso de la Sociedad Española de Inmunología 2013.

## **5.- GRANTED RESEARCH PROJECTS**

- **Competitive R&D projects**

- **2019-2021**: Estudio del potencial de las células mieloides supresoras como bioindicadores de la severidad del curso clínico y de respuesta al tratamiento en Esclerosis Múltiple. *Acción Estratégica en Salud 2018*. Ministerio de Ciencia, Universidad e Innovación. Total amount: 255.310€. Role: Associated Research. PI: Diego Clemente

-

**2016- 2019**: Estudio multicéntrico internacional de escalas de riesgo de infección en trasplante de órgano sólido. *Acción estratégica en Salud 2015*. Ministerio de Ciencia, Universidad e Innovación. **Total Amount**: 71.995 €. **Role**: Predoctoral student. PI: Javier Carbone

- **Projects supported by private entities**

**2014- 2021**: Evaluation of secondary antibody deficiency as risk factor of severe infection and its reconstitution with intravenous immunoglobulin. LABORATORIOS GRIFOLS, S.A.

## **6.- PARTICIPATION IN R&D AND INNOVATION CONTRACTS**

**2018- To date:** Estudio de las células mieloides supresoras como biomarcadores del curso clínico de la esclerosis múltiple y su implicación en estrategias reparadoras de la vaina de mielina dañada. Asociación Española para la Lucha contra la Esclerosis Múltiple; Asociación Torrijeña de Esclerosis Múltiple; Asociación de Esclerosis Múltiple de Toledo (ADEM-TO). 31.768 €.

**2017- To date:** Células mieloides supresoras: diana terapéutica endógena para el tratamiento de la esclerosis múltiple. Fundación Galletas Coral; Aciturri Aeronáutica S.L; Vesuvius Ibérica; Embutidos y Jamones España e Hijos. 16.400 €.

**2016- To date:** Métodos complementarios para la inmunomodulación de la actividad inflamatoria asociada a la esclerosis múltiple como herramienta neuro- reparadora. Asociación de Esclerosis Múltiple de Toledo (ADEM-TO). 7.000 €.